Remdesivir
Gilead’s remdesivir reduced the risk of death in 62% of severe COVID-19 patients, according to a new study.
The company released a statement which said: “The analysis demonstrated that remdesivir treatment was associated with the significantly improved clinical recovery and a 62 percent reduction in the risk of mortality compared to standard of care.”
This latest Phase 3 SIMPLE trial included 312 patients being treated with Gilead’s drug compared with 818 being in the standard care group with both groups showing a similar severity of the virus.
